Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
Source: SeekingAlpha
2026-07-03 10:49:07 ET
We are back to comment on Grifols, S.A. ( GRFS ), following the many latest changes since our last update (December 2025). We provided an equal-weight rating due to delayed product catalysts and elevated leverage. This proved to be the right call (Fig. 1), as Grifols' share price de-rated while the market (despite the Middle East escalation) turned positive, with the S&P 500 returning more than 8% in H1 2026....
Read the full article on Seeking Alpha
For further details see:
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
Grifols S.A.
NASDAQ: GRFS
GRFS Trading
0.98% G/L:
$7.23 Last:
494,616 Volume:
$7.29 Open:
GRFS Latest News
$6,538,647,175
559,676,571
N/A
69
N/A
Pharmaceuticals
Healthcare
ES
Sant Cugat del Valles
